Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 3

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
 -  
     -  
     (35) 
     -  
     (35)
  
    Net loss 
     -  
     -  
     -  
     -  
     (9,739) 
     (9,739)
  
    Balance as of March 31, 2025 
     22,930,411  
     23  
     203,103  
     (610) 
     (172,843) 
     29,673 
  
    Stock-based compensation 
     -  
     -  
     1,534  
     -  
     -  
     1,534 
  
    Sale of common stock for cash 
     3,654,847  
     4  
     22,267  
     -  
     -  
     22,271 
  
    Loss on foreign currency translation 
     -  
     -  
     -  
     (153) 
     -  
     (153)
  
    Net loss 
     -  
     -  

     (24,458) 
     (24,458)
  
    Balance as of June 30, 2025 
     26,585,258  
    $27  
    $226,904  
    $(763) 
    $(197,301) 
    $28,867 

 The accompanying notes are an integral
part of these unaudited condensed consolidated financial statements.

3

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30,
2024

(In thousands, except share amounts)

(Unaudited)

    Accumulated  

    Additional  
    Other  
       
    Total 

    Common Stock  
    Paid-In  
    Comprehensive  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Capital  
    Income (Loss)  
    Deficit  
    Equity 
  
    Balance as of December 31, 2023 
     17,950,776  
    $18  
    $159,143  
    $(799